期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 84, 期 4, 页码 497-505出版社
WILEY
DOI: 10.1038/clpt.2008.104
关键词
-
资金
- National Institutes of Health [R01-GM63674, R01-DA14211, K24-DA00417]
- University of Washington General Clinical Research Center [M01-RR00037]
Ritonavir diminishes methadone plasma concentrations, an effect attributed to Cyp3a induction, but the actual mechanisms are unknown. We determined ritonavir effects on stereoselective methadone pharmacokinetics and clinical effects (pupillary miosis) in healthy human immunodeficiency virus-negative volunteers. subjects received intravenous plus oral (deuterium-labeled) racemic methadone after no ritonavir, short-term (3-day) ritonavir, and steady-state ritonavir. acute and steady-state ritonavir, respectively, caused 1.5- and 2-fold induction of systemic and apparent oral r- and s-methadone clearances. ritonavir increased renal clearance 40-50%, and stereoselectively (S > R) increased hepatic methadone n-demethylation 50-80%, extraction twofold, and clearance twofold. Bioavailability was unchanged despite significant inhibition of intestinal P-glycoprotein. intestinal and hepatic Cyp3a was inhibited > 70%. ritonavir shifted methadone plasma concentration-miosis curves leftward and upward. rapid ritonavir induction of methadone clearance results from increased renal clearance and induced hepatic metabolism. induction of methadone metabolism occurred despite profound Cyp3a inhibition, suggesting no role for Cyp3a in clinical methadone metabolism and clearance. ritonavir may alter methadone pharmacodynamics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据